Pegasys market share
Common Questions and Answers about Pegasys market share
pegasys
More than 1,000 patients will be enrolled in PROGRESS and will be randomized to receive one of four dosing regimens of PEGASYS plus ribavirin for 48 weeks, followed by a 24-week treatment-free follow-up period. The four dosing regimens are:
* A fixed-dose induction (360 mcg) of PEGASYS given once every week for the first 12 weeks then the standard 180 mcg dose of PEGASYS for the following 36 weeks.
41 pegasys injections have been injected . PCR RNA stillL Showing 139000 IU/ml VIRAL LOAD. After 24 injections it was 80000 IU/ml. in spite decrease, viral load has been increased. Pegasys is not responding. Is there any other injection/ medicine available for quit treatment . Geno type is 1b.(***@****)92-0300-5304561
please help me .
For example, instead of having 15% chance of cure with pegasys alone, one could have maybe 20% (or 25%) chances of cure if pegasys would be combined with 520.
Pegasys can cause substantial side effects though...pegasys + 520 could be even tougher on side effects....so the question is how much one would be willing to take a risk to get to a cure.
Above is just my own estimate (based also on consultation with studyforhope, and the fact that 520 can lower hbsag just by 0.
The "lead in" is simply for the first four weeks you will begin your treatment with two drugs: Ribavirin and Interferon. At the start of the fifth week, Victrelis to create a three drug combo.
Victrelis is on its way to market and should be available within days.
s a great deal of variation from person to person, on average it seems to depend somewhat on which PEG you are doing. PEG IFN alpha 2a (Pegasys) has a branched PEG molecule and many report the peak of their sides to be 3-4 days after the shot. PEG IFN alpha 2b (Peg-Intron) has a much quicker onset with the peak seeming to come a day or two after the shot and diminishing right about the time Pegasys reachs it's peak.
Name change means absolutely nothing. It is a stock market company which will do anything to get their stocks up, including change names implying that they really have something big.
Their currently running phase-2 clinical trial in Australia will pretty much tell whether there is any real future for ARC-520. IMO, for hbeag negative it can only have some slight meaning in a combo with pegasys (or maybe some other medicine), slightly increasing the chances of cure...
pegasys is better, scientifically i am not sure, but most studies on hbv are done with 2a and that s what is used for treatment
Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1. Pharmasset expects to initiate a 12-week Phase 2b study of PSI-7977 in the fourth quarter of 2010.
you are right there is no drug on the market. And won't be for a while unless we as the community start speaking out.
These drug companies are doing real evil things by slowing down cures and better treatment plans for horrible virus as HBV so their antiviral market share will not disappear. This is pure eugenics.
The general public is not aware of this that HBV is AIDS of the liver. Not aware that waiting 3-4 years for somebody with advance stages of HBV is a death sentence.
we already have slow cures, so if rep9ac will be expensive few patients will be interested
if you donate you are not sure the drug will be on the market and will not reach US market for long unless they get US fda to approve
and when it will be on the market the cost will be very very high anyway.we had a post from a researcher many years ago, even copying the drug in another lab in israel or swiss cost is about 50.
Recommended
